dr. mcintyre on eribulin as first-line therapy in her2- breast cancer
Published 10 years ago • 735 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
1:17
dr. mcintyre on a phase ii study analyzing first-line eribulin mesylate
-
1:20
dr. o’shaughnessy on eribulin as first-line therapy for metastatic her2-negative breast cancer
-
3:40
treatment with eribulin in metastatic breast cancer
-
6:51
treatment with eribulin mesylate in metastatic breast cancer
-
5:25
eribulin in metastatic breast cancer
-
0:59
dr. linda vahdat on frontline eribulin plus trastuzumab in her2-positive mbc
-
2:42
eribulin as treatment for metastatic breast cancer
-
1:22
dr. brufsky on trastuzumab and eribulin for her2 metastatic breast cancer
-
9:49
patient selection for eribulin in breast cancer
-
8:21
improving the management of metastatic breast cancer, part ii
-
7:11
chemotherapeutics in metastatic breast cancer
-
3:00
eribulin’s role in triple-negative breast cancer
-
1:58
dr. alvarez on updated findings with eribulin in patients with her2 breast cancer
-
2:20
dr. llombart-cussac on eribulin in her2-negative metastatic breast cancer
-
2:09
the evolution of her2 targeting in metastatic breast breast cancer
-
2:08
dr. joyce o'shaughnessy on eribulin in metastatic breast cancer
-
1:18
dr. christopher twelves on eribulin mesylate in combination therapies for breast cancer
-
1:36
dr. chris twelves compares eribulin and capecitabine
-
57:18
navigating the expanding treatment arsenal for er /her2- breast cancer